Form 4: 10x Genomics Officer Sells Shares for Tax Obligations

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, sold 8,283 shares of Class A Common Stock to cover tax withholding obligations.

Summary

• Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (TXG), reported a sale of company stock.
• The transaction involved 8,283 shares of Class A Common Stock.
• The shares were sold at a price of $18.9983 per share.
• The total value of the shares sold is approximately $157,369.99.
• The purpose of the sale was to cover tax withholding obligations related to the vesting of restricted stock units.
• Following this transaction, Mr. Hindson beneficially owns 432,605 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The transaction is a routine sale of shares to cover tax obligations upon the vesting of restricted stock units, which is a common practice for executives and does not indicate a change in company fundamentals or management's outlook.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider transaction common across all industries when restricted stock units vest. It does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine tax-related sale and does not signal a change in the company's prospects or management's confidence.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

This Form 4 reports a routine insider sale of shares by Benjamin J. Hindson, President and Chief Scientific Officer, solely to cover tax withholding obligations associated with the vesting of restricted stock units. Such transactions are common and generally do not reflect a change in the insider's confidence in the company's long-term prospects or its operational performance. Therefore, this filing alone does not provide a basis for a change in investment recommendation, and a "hold" stance is maintained, pending further fundamental analysis.

Keywords

10x Genomics, TXG, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Benjamin J. Hindson, Officer Transaction, Director Transaction